Use of human prostrate cell lines in prostate cancer treatment

Details Use of human prostrate cell lines in prostate cancer treatment Use of human prostrate cell lines in prostate cancer treatment

2005-12-06

2005-12-06

Siew, Jeffrey (Department: 1642)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Cancer cell or component thereof

C424S093300

Reexamination Certificate

active

06972128

ABSTRACT:
The invention here relates to a product comprised of a cell line or lines intended for use as an allogeneic immunotherapy agent for the treatment of cancer in mammals and humans. All of the studies of cell-based cancer vaccines to date have one feature in common, namely the intention to use cells that contain at least some TSAs and/or TAAs that are shared with the antigens present in patients' tumour. In each case, tumour cells are utilised as the starting point on the premise that only tumour cells will contain TSAs or TAAs of relevance, and the tissue origins of the cells are matched to the tumour site in patients. A primary aspect of the invention is the use of immortalised normal, non-malignant cells as the basis of an allogeneic cell cancer vaccine. Normal cells do not possess TSAs or relevant concentrations of TAAs and hence it is surprising that normal cells are effective as anti-cancer vaccines. For prostate cancer, for example, a vaccine may be based on one or a combination of different immortalised normal cell lines derived from the prostate. The cell lines are lethally irradiated utilising gamma irradiation at 50–300 Gy to ensure that they are replication incompetent prior to use in the mammal or human.

REFERENCES:
patent: WO 93/06867 (1993-04-01), None
Berthon, P et al, 1995, Intl J Oncology, 6(2): 333-343.
Drexler et al (Leukemia and Lymphoma, 1993, 9:1-25).
Embleton et al (Immunol Ser, 1984, 23:181-207).
Hsu (in Tissue Culture Methods and Applications, Kruse and Patterson, Eds, 1973, Academic Press, NY, see abstract, p. 764).
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p4).
Dermer (Bio/Technology, 1994, 12:320).
Gura (Science, 1997, 278:1041-1042).
Jain (Sci. Am., 1994, 271:58-65).
Curti (Crit. Rev. in Oncology/Hematology, 1993, 14:29-39).
Hartwell et al (Science, 1997, 278:1064-1068).
Wu TT et al, 1998, Intl J cancer, 77(6): 887-94.
Triest JA et al, 1998, Clinical Cancer Res, 4(8): 2009-14.
Boon (Adv Can Res, 1992, 58:177-210).
The General Cell Collection on ECACC No. 95012613 downloaded on Apr. 5, 2005 from URL>http://www.ecacc.org.uk.
ATCC accession number CRL-1740 downloaded on Apr. 5, 2005 from URL>http://www.atcc.org/catalog
umSearch
umResults.cfm?atccNum=CRL-1740.
Ablin, J. Cancer Res. Clin. Oncol. 123: 583-594 (1997).
Tjoa et al., The Prostate 27: 63-69 (1995).
Vieweg et al., Cancer Research 54: 1760-1765 (1994).
Brenner et al., Journal of Urology, pp. 1575-1579 (1995) (abstract only).
Gorelik et al., Journal of Supramolecular Structure 12: 385-402 (1979) (abstract only).
Marble, Cancer Weekly Plus, p4(2) (1997).
Moran, American Medical News 42, 39, 23 (1999).

Affiliated with

Also associated with

Rating

Use of human prostrate cell lines in prostate cancer treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of human prostrate cell lines in prostate cancer treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of human prostrate cell lines in prostate cancer treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3504674